non-health resources utilization under routine medical practice derived in substantial costs when treating refractory painful due to cervical or lumbar radiculopathy. About two-thirds of the total costs were derived from non-health resources. OBJECTIVES: To analyze the Pregabalin (PGB) effect under routine medical practice on longitudinal health and non-health resources utilization (HRU) and derived costs of treating refractory painful Radiculopathy in Primary Care Setting (PCS) during 12-weeks. METHODS: A representative sample of PC centres included men and women above 18 years, with chronic pain (6-month or more) due to cervical (17%) or lumbar (83%) radiculopathy refractory to, at least, one previous analgesic [mean (SD) number of drugs; 2.6 (1.4)], in a prospective, naturalistic, 12-weeks two-visit study. Health resources included all-type medical visits, hospitalizations, complementary test and pharmacological and non-pharmacological therapies. Non-health included wages loses due to loss-work-days equivalents (LWDE = absenteeism days + days working with reduced productivity due to pain). Pain severity was measured by McGill-pain scale. Descriptive statistics and ANCOVA models were applied to compare 12-weeks periods of treatment. RESULTS: Onethousand-three-hundred-fifty-one PGB-naive patients [55.8% women, 56.7 (12.5) years] were analyzed: 490 (36%) switched to PGB as monotherapy (PGBm), 702 (52%) patients received PGB as add-on therapy (PGBadd-on), and in 159 (12%) previous treatment was replaced by a regimen not including PGB (Non-PGB). As compared to non-PGB, both PGBm and PGBadd-on showed significantly higher HRU reduction. The extra costs of drugs, particularly in PGB subgroups [€15.4 (39.1), €148.6 (109.1) and €145.3 (119.6), respectively (p < 0.0001 within and between groups)] was off-set by higher significant reductions in all other components of health costs (except non-pharmacological therapies in non-PGB group) yielding to a greater total cost reductions: €1203.3 (1805.6), €1423.2 (1650.0) and €1429.2 (1966.2), respectively (p < 0.001 within and p = 0.0004 between groups). CONCLUSION: In the primary care setting either add-on or monotherapy with pregabalin under routine medical practice was associated with a significant longitudinal reduction in HRU and total costs when compared with non-PGB therapy in subjects with painful radiculopathy of cervical or lumbar origin. OBJECTIVES: To analyze health and non-health resources utilization and derived costs of treating patients with refractory
peripheral NeP followed in PCS under routine medical practice. METHODS: A 12-weeks cross-sectional and retrospective analysis was carried out in year 2006 in a whole-nation representative sample of PC centres. Men and women above 18 years, with chronic pain (6-month or more) due to peripheral NeP (diabetic neuropathy, post-herpetic neuralgia or trigeminal neuralgia), and refractory to, at least, one previous analgesic were included in the analysis. Health resources included all-type medical visits, hospitalizations, complementary test and pharmacological and nonpharmacological therapies. Non-health included wages loses due to loss-work-days equivalents (LWDE = absenteeism days + days working with reduced productivity due to pain). Pain severity was measured by McGill-pain scale. RESULTS: One-thousandfour-hundred-thirty-nine subjects [58.8% women, 59.5 (12.7) years] were analyzed: 783 (54%) with diabetic painful neuropathy (DPN), 486 (34%) with post-herpetic neuralgia (PHN), and 170 (12%) with trigeminal neuralgia (TN). Last-week mean pain severity was 70.8 (16.1) mm with 60.2% declaring the pain as severe or worst the day of collecting data. Previous mean (SD) number of drugs was 2.3 (1.3), with a 30.3% on one-drug only; 72% on NSAIDs, 43% on paracetamol, 36% on opiods, 23% on antiepileptics, and 11% on antidepressants. Quarterly mean LWDE was 37.5 (27.6) days. Medical visits average per trimester was 9.7 (7.6), with 4.4% declaring one-hospitalization. Quarterly total mean cost was €2689 (2236); €983 (1394) direct health cost and €1706 (1440) indirect cost. Cost and health resources utilization were not associated to aetiological cause of pain. CONCLUSION: In the primary care setting, health and non-health resources utilization under routine medical practice derived in substantial costs when treating the associated refractory pain to peripheral neuropathies due to diabetes, postherpetic or trigeminal neuralgia. Two-thirds of the total costs were derived from non-health resources.
